Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis

Published:2023-02-10 Issue:2 Volume:13 Page:486
ISSN:2075-1729
Container-title:Life
language:en
Short-container-title:Life

Author:

Thong Lorraine¹,McElduff Enda James²,Henry Michael Thomas³

Affiliation:

1. Department of Clinical Medicine, Trinity College Dublin, D08 W9RT Dublin, Ireland

2. Department of Clinical Medicine, Royal College of Surgeons Ireland, D02 YN77 Dublin, Ireland

3. Department of Respiratory Medicine, Cork University Hospital, T12 YE02 Cork, Ireland

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrosing interstitial lung disease that occurs predominantly in the older population. There is increasing incidence and prevalence in IPF globally. The emergence of anti-fibrotic therapies in the last decade have improved patient survival though a cure is yet to be developed. In this review article, we aim to summarize the existing and novel pharmacotherapies for the treatment of IPF (excluding treatments for acute exacerbations), focusing on the current knowledge on the pathophysiology of the disease, mechanism of action of the drugs, and clinical trials.

Publisher

MDPI AG

Subject

Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics

Link

https://www.mdpi.com/2075-1729/13/2/486/pdf

Reference142 articles.

1. Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review;Hutchinson;Eur. Respir. J.,2015

2. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline;Raghu;Am. J. Respir. Crit. Care Med.,2022

3. Zheng, Q., Cox, I.A., Campbell, J.A., Xia, Q., Otahal, P., de Graaff, B., Corte, T.J., Teoh, A.K.Y., Walters, E.H., and Palmer, A.J. (2022). Mortality and survival in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. ERJ Open Res., 8.

4. Inflammation and immunity in IPF pathogenesis and treatment;Heukels;Respir. Med.,2019

5. Inui, N., Sakai, S., and Kitagawa, M. (2021). Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-beta and the Ubiquitin-Proteasome Pathway. Int. J. Mol. Sci., 22.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of pepsin levels in bronchial lavage in patients with interstitial lung disease and chronic cough;Respiratory Medicine;2024-11

2. Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan;Respiratory Investigation;2024-09

3. Integrating network pharmacology, experimental validation and molecular docking to reveal the alleviation of Yinhuang granule on idiopathic pulmonary fibrosis;Phytomedicine;2024-06

4. Effects of a Hydrolyzed Lignin Derivative on Bleomycin-Induced Pulmonary Fibrosis in Mice;Bulletin of Experimental Biology and Medicine;2024-05

5. Lessons From Prospective Longitudinal Follow-up of a French APECED Cohort;The Journal of Clinical Endocrinology & Metabolism;2024-04-12